Mario R Mautino
Overview
Explore the profile of Mario R Mautino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brincks E, Adams J, Wang L, Turner B, Marcinowicz A, Ke J, et al.
Oncotarget
. 2020 Jul;
11(25):2438-2461.
PMID: 32637034
Indoximod has shaped our understanding of the biology of IDO1 in the control of immune responses, though its mechanism of action has been poorly understood. Previous studies demonstrated that indoximod...
2.
Kumar S, Jaipuri F, Waldo J, Potturi H, Marcinowicz A, Adams J, et al.
Eur J Med Chem
. 2020 May;
198:112373.
PMID: 32422549
A series of different prodrugs of indoximod, including estesrs and peptide amides were synthesized with the aim of improving its oral bioavailability in humans. The pharmacokinetics of prodrugs that were...
3.
Parr B, Pastor R, Sellers B, Pei Z, Jaipuri F, Castanedo G, et al.
ACS Med Chem Lett
. 2020 Apr;
11(4):541-549.
PMID: 32292562
A class of imidazoisoindole (III) heme-binding indoleamine-2,3-dioxygenase (IDO1) inhibitors were optimized via structure-based drug design into a series of tryptophan-2,3-dioxygenase (TDO)-selective inhibitors. Kynurenine pathway modulation was demonstrated , which enabled...
4.
Kumar S, Waldo J, Jaipuri F, Marcinowicz A, Allen C, Adams J, et al.
J Med Chem
. 2019 Jul;
62(14):6705-6733.
PMID: 31264862
A novel class of 5-substituted 5-imidazo[5,1-]isoindoles are described as potent inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1). A structure-based drug design approach was used to elaborate the 5-imidazo[5,1-]isoindole core and to...
5.
Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian N, et al.
J Immunother Cancer
. 2018 Jun;
6(1):61.
PMID: 29921320
Background: Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919)...
6.
Sharma M, Shinde R, McGaha T, Huang L, Holmgaard R, Wolchok J, et al.
Sci Adv
. 2015 Nov;
1(10):e1500845.
PMID: 26601142
The tumor microenvironment is profoundly immunosuppressive. We show that multiple tumor types create intratumoral immune suppression driven by a specialized form of regulatory T cell (Treg) activation dependent on the...
7.
Metz R, Rust S, DuHadaway J, Mautino M, Munn D, Vahanian N, et al.
Oncoimmunology
. 2012 Dec;
1(9):1460-1468.
PMID: 23264892
Tryptophan catabolism by indoleamine 2,3-dioxygenase (IDO) alters inflammation and favors T-cell tolerance in cancer, but the underlying molecular mechanisms remain poorly understood. The integrated stress response kinase GCN2, a sensor...
8.
Rossi G, Mautino M, Awwad D, Husske K, Lejukole H, Koenigsfeld M, et al.
J Immunother
. 2008 Jun;
31(6):545-54.
PMID: 18528300
Owing to the absence of alphaGal epitopes in human cells and constant stimulation of the immune system by the symbiotic bacterial flora, humans develop high titers of natural antibodies against...
9.
Rossi G, Mautino M, Unfer R, Seregina T, Vahanian N, Link C
Cancer Res
. 2005 Nov;
65(22):10555-61.
PMID: 16288048
The hyperacute immune response in humans is a potent mechanism of xenograft rejection mediated by complement-fixing natural antibodies recognizing alpha(1,3)-galactosyl epitopes (alphaGal) not present on human cells. We exploited this...
10.
Rossi G, Mautino M, Morgan R
Hum Gene Ther
. 2003 Mar;
14(4):385-91.
PMID: 12659679
The goal of the present report was to determine if lentiviral vectors could mediate gene transfer into murine terminally differentiated macrophages and mature B lymphocytes as a new strategy of...